首页 | 本学科首页   官方微博 | 高级检索  
     

结直肠癌同时性肝转移同期与分期手术切除疗效比较
引用本文:王立军,闫晓峦,王崑,包全,孙谊,王宏伟,金克敏,邢宝才. 结直肠癌同时性肝转移同期与分期手术切除疗效比较[J]. 中华胃肠外科杂志, 2014, 0(10): 1009-1013
作者姓名:王立军  闫晓峦  王崑  包全  孙谊  王宏伟  金克敏  邢宝才
作者单位:北京大学肿瘤医院暨北京市肿瘤防治研究所肝胆胰外一科 恶性肿瘤发病机制及转化研究教育部重点实验室, 100142
基金项目:国家自然科学基金(81371868)
摘    要:目的:比较结直肠癌同时性肝转移患者原发灶和肝转移灶同期与分期切除的近期和远期结局。方法回顾性分析北京肿瘤医院肝胆胰外一科2003年1月至2011年12月间的64例结直肠癌合并同时性肝转移患者的临床及术后随访资料,其中行原发灶和肝转移灶同期切除者20例(同期切除组),分期切除者44例(分期切除组)。结果同期切除组Clavien-Dindo 1、2和3级并发症发生率分别为10.0%(2/20)、15.0%(3/20)和15.0%(3/20),分期切除组分别为13.6%(6/44)、13.6%(6/44)和22.7%(12/44),差异无统计学意义(P>0.05)。同期切除组1、2和3年总体生存率分别为85.0%、59.6%和37.2%,分期切除组分别为90.9%、68.2%和47.1%,差异亦无统计学意义(均P>0.05)。两组中位无病生存时间分别为6月和7月,差异亦无统计学意义(P>0.05)。多因素预后分析显示,原发灶淋巴结阳性(P=0.020)和肝切除术前CEA水平大于20μg/L(P=0.017)是影响患者总体生存的独立危险因素;复发后有机会接受根治性局部治疗联合化疗则是一项保护性因素(P=0.001);而手术时机(同期或分期切除)与患者总体生存无关(P>0.05)。结论对于结直肠癌同时性肝转移,选择同期或分期切除并不影响患者的术后并发症发生率和远期生存率。

关 键 词:结直肠肿瘤  肝转移,同时性  同期肝切除  分期肝切除  预后

Simultaneous versus staged liver resection of synchronous liver metastasis from colorectal cancer
Wang Lijun,Yan Xiaoluan,Wang Kun,Bao Quan,Sun Yi,Wang Hongwei,Jin Kemin,Xing Baocai. Simultaneous versus staged liver resection of synchronous liver metastasis from colorectal cancer[J]. Chinese journal of gastrointestinal surgery, 2014, 0(10): 1009-1013
Authors:Wang Lijun  Yan Xiaoluan  Wang Kun  Bao Quan  Sun Yi  Wang Hongwei  Jin Kemin  Xing Baocai
Affiliation:( Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education), Department of Hepatopancreaticobiliary Surgery, Peking University Cancer Hospital & Institute, Bering 100142, China)
Abstract:Objective To compare the short- and long-term outcomes of patients with synchronous colorectal liver metastases receiving either simultaneous or staged hepatectomy. Methods Clinical and follow-up data of 64 patients with synchronous colorectal liver metastasis who underwent either simultaneous or staged hepatectomy between January 2003 and December 2011 in our hospital were reviewed retrospectively. Among them 20 patients underwent simultaneous resection of colorectal cancer and liver metastasis (simultaneous group) and 44 patients underwent staged operations (staged group). Results The Clavien-Dindo grade 1, 2, 3 complication rates in simultaneous group were 10.0%, 15.0% and 15.0% respectively, and were staged group 13.6%, 13.6% and 22.7% respectively in staged group, and the difference was not statistically significant (P〉0.05). The 1-, 2- and 3-year overall survival rates in simultaneous group were 85.0%, 59.6% and 37.2% respectively, compared with 90.9%, 68.2% and 47.1% in staged group, and the difference was not statistically significant (P〉0.05). The median disease-free survival time in simultaneous group was 6 months versus 7 months in the staged group, which was comparable (P〉0.05). Multivariate analysis revealed that positive primary lymph-node (P=0.020), prehepatectomy CEA〉20 μg/L (P=0.017) were independent risk factors of overall survival, and having the opportunity to receive local radical therapy combined with chemotherapy after recurrence was a protective factor (P=0.001), while the timing of resection (simultaneous or staged strategy) did not reach statistical significance according to overall survival (P〉0.05). Conclusions For synchronous colorectal liver metastasis there are no significant differences in postoperative complication rate and long-term survival between curative simultaneous and staged resection.
Keywords:Colorectal neoplasms  Liver metastases,synchronous  Simultaneous resection  Staged resection  Prognosis
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号